Bacteriedodende virussen, Belgische koffie, gerecycleerde fruitschillen en paddenstoelenplastic: het zijn slechts enkele van de markante technologieën opgeworpen door elf

Follow the most interesting biotech companies accounts on Bluesky. Browse 3+ starter packs to discover biotech companies communities.

From First Date to Long-term Commitment: Lessons Learned from $200M of upfronts at Mammoth In biotech, a single strategic partnership can transform a company’s trajectory – for better o…

Join us at at Boulder Falls Event Center next to Western University of Health Sciences in Lebanon to showcase biotech innovation, talent, and investment across the region.

Shared lab spaces provide a streamlined launchpad, offering benches as well as a diverse network of industry mentors. Shared lab spaces provide a streamlined launchpad, offering benches as well as a d...

Two American companies, Manhattan Genomics and Bootstrap Bio, both launched with the goal of creating gene-edited babies to prevent serious diseases, have ceased operations. Manhattan Genomics closed after only four months due to internal conflicts between cofounders and complex corporate governance issues involving a Cayman Islands entity. Bootstrap Bio, meanwhile, ended active operations citing financial difficulties and the arrest of its former chief science officer on charges of attempted child sex trafficking, which the CEO stated occurred after the company had already stopped operating. Both startups were exploring germline editing, a controversial technique that modifies embryos and passes changes to future generations. Safety and ethical concerns remain a major barrier, as off-target genetic changes and potential use for non-medical enhancements such as intelligence or appearance continue to worry researchers. While these companies struggled, other embryo-editing ventures like Preventive have attracted substantial investment from high-profile figures in tech, signaling ongoing interest despite regulatory and ethical hurdles. The closures highlight both the financial and moral complexities of commercial germline gene editing in humans, as well as the difficulty of building a sustainable business in this controversial field.